Opinion|Videos|December 14, 2023
A Patient’s Experience With Initial Treatment for RCC
Author(s)Thomas E. Hutson, DO, PharmD, Kacie Ellis, RN
Mr. Fuentes felt it was important to understand the range of potential side effects to anticipate how his body would potentially react to treatment for RCC and determine his physical abilities and support needs, but was most focused on whether his first post-treatment scan showed tumor shrinkage.
Advertisement
Episodes in this series
Advertisement
Related to this article
Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
2
Where Does Intensity-Modulated Proton Therapy Fit in Prostate Cancer?
3
FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC
4
IMS 2026: Key Updates Across The Multiple Myeloma Paradigm
5